- Patient/Guest
- Phlebotomist
- Updates
| CEA Fluid | - |
|---|
|
Measure CEA in body fluid |
||
 |
Synonym | See updates |
 |
Test Code | CDBIOPR0038 |
 |
Test Type | Biochemistry |
 |
Pre-Test Condition | See updates |
 |
Report Availability | 2 D(s) |
 |
# Test(s) | 1 |
| Test details | Sample Report |
|---|---|
| CEA Fluid |
|
|
Synonym | See updates | |
|
Test Code | CDBIOPR0038 | |
 |
Test Category | Cancer | |
|
Pre-Test Condition | See updates | |
 |
Medical History | See updates | |
|
Report Availability | 2 D(s) | |
 |
Specimen/Sample | Body fluid; 5 mL; St Cont | |
 |
Stability @21-26 deg. C | 6 Hr(s) | |
 |
Stability @ 2-8 deg. C | 24 Hr(s) | |
 |
Stability @ Frozen | NA | |
|
# Test(s) | 1 | |
 |
Processing Method | Chemiluminescence | |
| **Carcinoembryonic Antigen Body Fluid****FDA Status**: FDA-approved for tumor marker testing.**Other Names**: CEA Fluid Test, Tumor Marker Fluid Analysis.**Historical Breakthrough**: Developed in the 1970s to monitor cancer, advancing oncology.**Key Purpose and Impact**: Measures CEA in body fluids to diagnose or monitor cancers (e.g., pleural effusion-related).**Preparation and Patient History**: Fluid sample; report cancer history or fluid accumulation.**Consent Requirement**: Varies based on fluid collection method.**Clinical Value**: Sensitivity ~90%; specificity ~95%; detects cancer in ~70% of cases; guides therapy.**References Cited**: Testing.com Oncology Tests 2023; Labcorp CEA Fluid Test 2025; UpToDate Tumor Markers 2025 |